Patient population and data management
tumor, PDAC, AJCC, Cancer
MALIGNANT TUMORS, LIVER METASTASIS, TUMOR, CANCER
This study was approved by the Ethics Committee of Sun Yat-sen Memorial Hospital (SYSMH), and patient informed consent was waived for this retrospective research. Between July 2010 and July 2020, a total of 330 patients from SYSMH North District, 201 cases from SYSMH South District (North District and South District) and 251 patients from the First Affiliated Hospital of Sun Yat-Sen University (FAHSYSU) diagnosed as PDAC identified by histopathological examination after upfront surgery were enrolled in this study. The Exclusion criteria included the following: (1) lack of enhanced MRI test within 2 weeks before surgery; (2) low-quality MRI image; (3) history of previous or coexisting other malignant tumors; (4) synchronous liver metastasis (occurrence at base line or within 3 months after surgery); (5) any local or systemic treatment at or before the baseline MRI examination; (6) follow-up for patients without liver metastasis after operation less than 1 year; (7) Patients who died within 3 months after surgery.Several clinical characteristics, including age, sex, serum tumor biomarkers, and liver function tests were collected before surgery. All pancreas pathological specimens were got from the operation tissue. The pathological stage was referred to the 8th edition American Joint Committee on Cancer (AJCC) [Finally, 204 patients were enrolled into the final analysis. Among them, 68 cases came from SYSMH South District, 114 cases came from SYSMH North District, and 22 cases were from FAHSYSU. Patients from three centers were divided randomly (7:3) into the development (n = 143, 70.1%) and validation (n = 61, 29.9%) cohort (Fig. Workflow of this study